

# NeoVista presents a revolutionary new treatment for Wet Age-related Macular Degeneration

**Barcelona, 7 February 2008.** NeoVista Inc., a California-based medical device company, presented its revolutionary new technology for treating Wet Age-Related Macular Degeneration (AMD) today in Barcelona. The results from prior feasibility studies lends hope to an effective treatment by means of a single surgical procedure that not only checks the development of AMD, but also shows the promise of improving a large number of patients' vision, thus enabling them to perform everyday activities again.

The event was hosted by **Dr. Borja Corcóstegui**, Director of the Ocular Microsurgery Institute (IMO) in Barcelona, who is serving as a principle investigator for the NeoVista sponsored CABERNET clinical study. Also on the program were **John N. Hendrick**, President and CEO of NeoVista; **Dr. Eugene de Juan**, vice chairman of ForSight Labs and co-inventor of the NeoVista technology; and **Dr. Benjamín Guix**, radiotherapist and director of the IMOR Foundation, Medical Institute for Radiotherapy and Oncology, also in Barcelona.

Dr. Corcostegui stated, "I am pleased to serve as a Principle Investigator in the CABERNET Study. A surgical approach to treating this terrible disease is an exciting idea and I look forward to observing the outcomes of this multi-center trial."

AMD is one of the most serious conditions that affect the macula (the part of the eye responsible for central vision) and is the main cause of irreparable blindness in people over 60. If left untreated, the condition gives rise to a rapid loss of central vision.

There are currently more than 164,000 people with wet AMD in Spain, and 30,000 new cases are detected every year. These figures are expected to increase in the coming years as the population ages.

NeoVista has begun a definitive clinical trial called CABERNET (**CNV Secondary to AMD Treated with BEta Radiation Epiretinal Therapy**) to demonstrate the effectiveness of the NeoVista treatment protocol compared to the results obtained with anti-VEGF therapy alone.

This study will recruit 495 patients in 40 clinical sites throughout the world, including the Ocular Microsurgery Institute (IMO) in Barcelona, which will begin its initial treatments in February 2008.

John N. Hendrick, President and CEO of NeoVista, stated "I am pleased with the attendance at today's event. There is clearly a strong local interest in our surgical approach to treating wet AMD. All of us at NeoVista look forward to the continued expansion of CABERNET study sites and the ultimate results of this important study."

## About NeoVista, Inc.

NeoVista, Inc. is a privately held development-stage medical device company based in Fremont, California. Current investors include Versant Ventures, SV Life Sciences, the Carlyle Group, Accuitive Ventures, Essex Woodlands Health Ventures, and MPM Capital.

For more information about the company, their novel treatment approach, or the CABERNET clinical trial, please visit the company's Web site at <http://www.neovistainc.com/>.

**For further information, please contact to:**

**Tony Moses**  
**NeoVista, Inc.**  
[tmoses@neovistainc.com](mailto:tmoses@neovistainc.com)